Bronchopulmonary dysplasia and surfactant

Area of Science:

• Neonatal Medicine
• Respiratory Physiology

Background:

• Bronchopulmonary dysplasia (BPD) is a major complication in preterm infants surviving mechanical ventilation.
• Exogenous surfactant reduces respiratory distress syndrome (RDS) severity, but BPD incidence has not decreased.

Purpose of the Study:

• To analyze the effect of exogenous surfactant administration on BPD incidence and severity.
• To investigate the changing pathogenesis of BPD in the context of modern neonatal care.

Main Methods:

• Review of existing evidence on surfactant therapy in preterm infants.
• Analysis of BPD incidence and mortality data in relation to surfactant use.

Main Results:

• Surfactant therapy reduces RDS and may decrease neonatal mortality and BPD occurrence, especially when administered prophylactically or early.
• The overall incidence of BPD has not significantly decreased, possibly due to increased survival of high-risk infants.
• While severe BPD cases may be less common, the overall impact of surfactant on BPD incidence remains debated due to conflicting data.

Conclusions:

• Exogenous surfactant can reduce mortality and BPD risk in preterm infants with RDS.
• The changing nature of BPD and multiple contributing factors complicate the assessment of surfactant's effect on overall incidence.
• Prophylactic or early surfactant administration appears more beneficial than late treatment for reducing mortality and BPD.